Efficacy of a novel phosphodiesterase inhibitor, E6005, in patients with atopic dermatitis: An investigator-blinded, vehicle-controlled study

Autor:	Shunji Matsuki, Maiko Nomoto, Seiichiro Hojo, Hideto Akama, Kyoko Matsuguma, Fuminori Ohba, Shuhei Imayama
Rok vydání:	2016
Předmět:	Adult Male 0301 basic medicine medicine.medical_specialty Phosphodiesterase Type 4 Phthalic Acids Dermatology Administration Cutaneous Dermatitis Atopic Ointments 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine medicine Humans In patient Phosphodiesterase inhibitor PDE4 Inhibitors Transdermal Dose-Response Relationship Drug business.industry Atopic dermatitis medicine.disease Bioavailability Clinical trial Treatment Outcome 030104 developmental biology Quinazolines Phosphodiesterase 4 Inhibitors business
Zdroj:	Journal of Dermatological Treatment. 27:467-472
ISSN:	1471-1753 0954-6634
DOI:	10.3109/09546634.2016.1157257
Popis:	Phosphodiesterase type 4 (PDE4) inhibition is a well-known anti-inflammatory mechanism. However, the clinical use of PDE4 inhibitors has been compromised by the occurrence of mechanism-associated adverse reactions, which often limit the maximum tolerated dose. To minimize systemic exposure, a topically active PDE4 inhibitor with low transdermal bioavailability could be clinically useful. The purpose of this study was to evaluate the efficacy of a novel topical PDE4 inhibitor, E6005, in patients with atopic dermatitis.This randomized, investigator-blinded, vehicle-controlled, multiple ascending dose study included 40 adult male patients with atopic dermatitis, who were randomly assigned to 10 days of treatment with either E6005 ointment (0.01, 0.03, 0.1 or 0.2%) or vehicle ointment.Of 81 patients screened, 40 who had typical lesions on their posterior trunk were randomized into the study. One patient receiving 0.03% E6005 treatment discontinued because of acute gout and one receiving vehicle treatment discontinued because of progression of atopic dermatitis. The targeted lesion severity scores decreased in a concentration-dependent manner in patients treated with E6005. This drop was significant in the 0.2% E6005 ointment treatment group (mean percent change: -54.30%, p = 0.007).E6005 ointment showed anti-inflammatory efficacy in adult patients with atopic dermatitis.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09fa0ca6125dd331f67a92d0fc30a355 https://doi.org/10.3109/09546634.2016.1157257 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.